- Home
- THH vs ACIU Comparison
THH vs ACIU Comparison
Compare THH & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THH
- ACIU
- Stock Information
- Founded
- THH 2013
- ACIU 2003
- Country
- THH Japan
- ACIU Switzerland
- Employees
- THH N/A
- ACIU N/A
- Industry
- THH
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- THH
- ACIU Health Care
- Exchange
- THH Nasdaq
- ACIU Nasdaq
- Market Cap
- THH 226.7M
- ACIU 213.3M
- IPO Year
- THH 2025
- ACIU 2016
- Fundamental
- Price
- THH $9.22
- ACIU $3.52
- Analyst Decision
- THH
- ACIU Strong Buy
- Analyst Count
- THH 0
- ACIU 2
- Target Price
- THH N/A
- ACIU $10.00
- AVG Volume (30 Days)
- THH 835.7K
- ACIU 400.2K
- Earning Date
- THH 11-20-2025
- ACIU 10-31-2025
- Dividend Yield
- THH N/A
- ACIU N/A
- EPS Growth
- THH N/A
- ACIU N/A
- EPS
- THH 0.02
- ACIU N/A
- Revenue
- THH $20,390,561.00
- ACIU $36,362,036.00
- Revenue This Year
- THH N/A
- ACIU N/A
- Revenue Next Year
- THH N/A
- ACIU $1,022.98
- P/E Ratio
- THH $551.40
- ACIU N/A
- Revenue Growth
- THH 14.93
- ACIU 86.71
- 52 Week Low
- THH $4.20
- ACIU $1.43
- 52 Week High
- THH $12.00
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- THH N/A
- ACIU 61.55
- Support Level
- THH N/A
- ACIU $2.63
- Resistance Level
- THH N/A
- ACIU $3.70
- Average True Range (ATR)
- THH 0.00
- ACIU 0.31
- MACD
- THH 0.00
- ACIU 0.00
- Stochastic Oscillator
- THH 0.00
- ACIU 77.39
About THH TryHard Holdings Limited Ordinary Shares
Tryhard Holdings Ltd is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. Its principal businesses are (i)event curation ; (ii) consultancy and management services; (iii) sub-leasing of entertainment venues; and (iv) ownership and operation of restaurants. The company has four reportable segments: consultancy and management, event curation, sub-leasing and restaurant operation. The maximum of its revenue is derived from the consultancy and management segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.